Urodynamic studies by advanced practice providers surged 30% over the past 5 years, highlighting a shift in practice dynamics. Understanding these trends could optimize resource allocation and guide training focus in urology departments. tinyurl.com/2bxaoj65

A huge congratulations to Dr. Greg Raster on his successful @Endo_Society fellowship match! 👏🏼 @UChicagoUrology @Yale_Urology

We are proud to announce Yale Urology’s endourology fellowship match for 2027-2028—congratulations, @GregRaster, MD! #FellowMatch @YaleMed | @UChicagoUrology | @UChicagoUro

Excited to announce we will be keeping our very own Dr. Cabral as our SUO fellow! Congratulations Josh! 👏🏼

Many thanks to @BladderCancerUS! Looking forward to doing this work with the team at @uchicagosurgery SIHSR and with excellent collaborators and mentors.

Congrats to @marthpodi, recipient of BCAN's inaugural $250K Patient-Centered Clinical Research Award. His work at @UChicagoMed will advance access, quality, and patient experience in bladder cancer care. A major step forward for patient-centered outcomes.

Great to have Dr. Behfar Ehdaie give the annual Belfield lecture at @ChiUroSociety tonight. Full house and great discussions!

I hear about this. This is not uncommon and it bothers me: Patient has cancer which is getting worse and causing pain Waits days for doctors appointment See the doctor. Scans ordered. But now waits days for an appointment slot to get the scans Scan is done and shows the cancer has worsened. Doctor prescribes new treatment Waits for days as insurance denies new treatment. Peer to peer call needed. Finally, treatment is approved. Waits for days again because chemotherapy appointments are backed up. Finally, the patient receives the treatment. But a month has passed. The cancer has progressed more. All of this with good private insurance. Imagine without. Oncology has advanced rapidly. Our medicines are very specialized. They require a lot of time, expertise, resources. Oncologists are stretched thin. It’s not the type of work that you can easily fill without compromising care. Many patients receive complex chemo and when there is a complication they end up without access to specialized care. We need to expand the oncology work force and limit the burnout that is causing good oncologists to leave patient care for other jobs or retire. There is no question we have made remarkable progress against cancer. And several promising new treatments are on the horizon. Will we have the resources to administer them safely and to all those who need it?

📆 ICYMI: September is Prostate Cancer Awareness Month, and we recently brought together Dr. Neeraj Agarwal, and Dr. Tyler Seibert with host Dr. Parth Modi for a multidisciplinary discussion on the evolving landscape of prostate cancer care. They examine: - Emerging data from ongoing trials - PSMA PET and its role in detection and treatment planning - Radioligand therapies and alpha emitters - Strategies for metastatic and castration-resistant disease - Individualizing treatment intensity to optimize outcomes 🎧 Listen here: na2.hubs.ly/H01bSg10 #ProstateCancer #UrologicOncology #ClinicalTrials #MedicalOncology #URO259

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? @neerajaiims and @TylerSbrt join @marthpodi to discuss emerging data and evolving treatment strategies in prostate cancer care #URO259 @_backtableONC na2.hubs.ly/H011wjd0

Mixed emotions seeing our incredible @uchicagosurgery #SIHSR research scholars graduate from our program. Looking forward to great things from Dr. Andrea Liu and Dr. Andrew Folkerts in the future!

Looking forward to walking next Sat in the Chicago @BladderCancerUS walk to raise awareness for bladder cancer. If you're interested in donating or joining our @UChicagoUro team please use the link below. secure2.convio.net/bcani/sit…

Approximately 30% of advanced practice clinicians moved practices within 3 years of first billing Medicare. ja.ma/3EUscBY

Bladder cancer at #AUA25 with a lot of good lessons. Not least of these: companies who want their product to succeed in the BCG-refractory space should fund a trial with a Gem/doce control.

Our APD Dr. Reynolds and PGY3 Dr. Joshua Cabral will be representing @UChicagoUrology at AMEC this weekend! Looking forward to meeting everyone!

Last week, CUS President Dr. Sarah Adelstein delivered an inspiring keynote on the state of Urogynecology & Pelvic Recon. Thank you for your tireless leadership this year! We’re excited to welcome Dr. Mark Wille from Cook County Health as incoming CUS President for 2025-2026!

Postdoc Opportunity – Urology Research at UChicago! 🚨 Join my team to advance Prostate Cancer research! Key roles: clinical research, trials, data management, manuscript & grant writing. 💰 Salary: $61K-$74K (NIH scale) 📍 Location: University of Chicago 📩 Apply: Send CV & research goals to Abhinav.Sidana@bsd.uchicago.edu 🔗 More info: bsdpostdoc.uchicago.edu #Postdoc #Urology #Research #Hiring @AmerUrological

Very important study! One of the main criticisms of Gem/Doce is that "all the data is retrospective" This prospective study has results that are even better (92% CR at 1 year) Looking forward to larger studies and BRIDGE results

2026 Urology applicants ‼️ Our sub-I applications are now open! ➡️ Apply on VSLO: vslo.aamc.org/vslo/#/electiv… ➡️ Scan the QR code or visit surgery.uchicago.edu/section…… to learn more about our program ➡️ Scholarship information: pritzker.uchicago.edu/academ… DM us with questions! 📩

Happy Match Day and a huge WELCOME to our first class of 4!!! 🥳🥳 @LaHekky @dvelasquezu @pearce_k_med @m_vallejosling